{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 6 of 92', 'CR845-CLIN3103', '9. Has at least 2 single-pool Kt/V measurements 1.2, or at least', '2 urea reduction ratio measurements 65%, or 1 single-pool', 'Kt/V measurement 1.2 and 1 urea reduction ratio', 'measurement >65% on different dialysis days during the', '3 months period prior to screening;', '10. Prior to randomization:', 'a.', 'Has completed at least four out of eight Worst Itching', 'Intensity Numerical Rating Scale (NRS) worksheets from', 'the start of the 7-day Run-in Period up to and including the', 'pre-randomization assessment on Day 1;', 'b. Has a mean baseline Worst Itching Intensity NRS score', '>5, defined as the average of all non-missing scores', 'reported from the start of the 7-day Run-in Period up to', 'and including the pre-randomization assessment on Day 1.', 'To be eligible for inclusion into the Open-label Extension Phase of', 'the study, each patient will have to fulfill the additional following', 'criteria at the time of entry into the Open-label Extension Phase:', '11. Has received at least 30 doses of the planned 36 doses of study', 'drug during the Double-blind Phase of this study;', '12. Has a prescription dry body weight >40 kg;', '13. Continues to meet inclusion criteria 1 through 7.', 'Exclusion Criteria:', 'A patient will be excluded from the Double-blind Phase of the study if', 'any of the following criteria are met:', '1. Known noncompliance with dialysis treatment that in the', 'opinion of the Investigator would impede completion or', 'validity of the study;', '2. Scheduled to receive a kidney transplant during the study;', '3.', 'Known history of allergic reaction to opiates, such as hives', '(Note: side effects related to the use of opioids, such as', 'constipation or nausea, would not exclude patients from the', 'study).', '4. Has a concomitant disease or a history of any medical', 'condition that, in the opinion of the Investigator, could pose', 'undue risk to the patient, impede completion of the study', 'procedures, or would compromise the validity of the study', 'measurements, including, but not limited to:', 'a.', 'Known or suspected history of alcohol, narcotic, or other', 'drug abuse, or substance dependence within 12 months', 'prior to screening;', 'b. Significant systolic or diastolic heart failure (eg, New', 'York Heart Association Class IV congestive heart failure', '[Appendix 1, Section 14.1]);', 'c.', 'Severe mental illness or cognitive impairment (eg,', 'dementia);', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 7 of 92', 'CR845-CLIN3103', 'd. Any other relevant acute or chronic medical or', 'neuropsychiatric condition within 3 months prior to', 'screening (eg, diagnosis of encephalopathy, coma,', 'delirium);', '5.', 'New or change of treatment received for itch including', 'antihistamines and corticosteroids (oral, IV, or topical) within', '14 days prior to screening;', '6.', 'New or change of prescription for opioids, gabapentin, or', 'pregabalin within 14 days prior to screening;', '7.', 'Received another investigational drug within 30 days prior to', 'the start of screening or is planning to participate in another', 'clinical study while enrolled in this study;', '8.', 'In the opinion of the Investigator, has pruritus attributed to a', 'cause other than ESRD or its complications (eg, patients with', 'concomitant pruritic dermatological disease or cholestatic liver', 'disease) (Note: Patients whose pruritus is attributed to ESRD', 'complications, such as hyperparathyroidism,', 'hyperphosphatemia, anemia, or the dialysis procedure or', 'prescription may be enrolled);', '9.', 'Has localized itch restricted to the palms of the hands;', '10. Has pruritus only during the dialysis session (by patient', 'report);', '11. Is receiving ongoing ultraviolet B treatment and anticipates', 'receiving such treatment during the study;', '12. Participated in a previous clinical study with CR845.', 'A patient will be excluded from the Open-label Extension Phase of', 'the study if any of the additional following criteria are met at the', 'time of entry into the Open-label Extension Phase:', '13. Completed the Double-blind Phase of this study but exhibited', 'adverse events during the course of the Treatment Period that', 'may preclude continued exposure to the study drug;', '14. Was noncompliant with protocol procedures during the', 'Double-blind Phase of this study which is indicative of an', 'inability to follow protocol procedures;', '15. Has developed a concomitant disease or any medical condition', 'that, in the opinion of the Investigator, could pose undue risk to', 'the patient, impede completion of the study procedures, or', 'would compromise the validity of the study measurements.', 'STUDY DESIGN', 'This is a multicenter, randomized, double-blind, placebo-controlled', 'study to evaluate the safety and efficacy of IV CR845 at a dose of', '0.5 mcg/kg administered after each dialysis session. The study', 'includes a Double-blind Phase, an Open-label Extension Phase, and a', 'Follow-up Period.', 'Double-blind Phase', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}